SBC Medical Group Holdings Inc., a Japanese owner and operator of aesthetic medical clinics, has laid the groundwork for substantial growth in 2026 following a year of strategic initiatives. The company expanded its franchise network, entered new markets, and optimized pricing, resulting in improved financial performance and increased visibility among investors.
As of September 30, 2025, SBC Medical operated 258 franchise locations, a 15% year-over-year increase. The company's revised pricing strategy led to a 5% sequential rise in average revenue per customer in the third quarter of 2025, driven by pricing optimization and a focus on higher-revenue customers. SBC Medical also expanded its service offerings to include specialized medical services such as plastic surgery and infertility treatment, strengthening its competitive position.
International expansion was a key focus, with entry into Singapore and Thailand. In early 2026, SBC announced its first U.S. expansion. The company also launched new brands, including "Neo Skin Clinic" and "Hada no Aozora Clinic" in Tokyo, the latter using a hybrid dermatology model combining insurance-covered and private-pay treatments.
Acquisitions played a significant role in SBC's growth strategy. The company acquired MB Career Lounge Co. Ltd., a provider of management support services for medical institutions, and integrated Waqoo, a related subsidiary, to accelerate R&D in clinical areas such as AGA (androgenetic alopecia) and orthopedics. These moves aim to enhance SBC's offerings and competitive edge.
Financially, SBC Medical reported a significant improvement in net profit in the third quarter of 2025, returning to a more typical cost structure after IPO-related expenses. Average revenue per visit rose 5% sequentially to $298 and 8.4% from the first quarter of 2025, with a repeat customer rate of 72%.
The company's inclusion in the Russell 3000 Index increased its visibility among institutional and individual investors, as about $10.6 trillion in U.S. assets are benchmarked against Russell U.S. indexes. SBC Medical also announced a stock buyback program of up to $5 million, reflecting confidence in its growth prospects.
To capitalize on cosmetic tourism, SBC is targeting Chinese consumers visiting Japan for procedures, enhancing Chinese-language services and marketing on Chinese social media. In Singapore, the company expanded its collaboration with Aesthetic Healthcare Holdings Pte. Ltd., which operates multiple medical aesthetics brands. In Thailand, SBC signed an e-consulting agreement with BLEZ ASIA Co. Ltd. to support a new dermatological clinic in Bangkok.
The global cosmetic surgery and procedure market, valued at $122.08 billion in 2022, is expected to grow at a CAGR of 14.7% from 2023 to 2030. SBC Medical's strategic moves position it to leverage this growth. With a strong cash position of $125 million at the start of 2025 and a clear expansion strategy, the company is poised for a successful 2026.
